Shang­hai biotech’s VEGF bis­pe­cif­ic en­ters Phase 1 tri­al in Chi­na

LaNo­va Med­i­cines has ad­vanced its PD-1xVEGF bis­pe­cif­ic an­ti­body to a first in-hu­man tri­al in Chi­na af­ter se­cur­ing $42 mil­lion in a Se­ries C1.

The Shang­hai …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER